Guardion Health Sciences Initiates Placebo-Controlled Clinical Trial Involving Proprietary GlaucoCetin® Product

Guardion Health Sciences Announces Financial Results for the Three Months and Year Ended December 31, 2020

Guardion Health Sciences Regains Compliance with Nasdaq Minimum Bid Price Rule

Guardion Health Sciences to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference

Guardion Health Sciences Announces 1-for-6 Reverse Stock Split Effective Pre-Market Opening on Monday, March 1, 2021

Malaysia’s Ho Wah Genting Berhad Advises Guardion Health Sciences That It Has received Regulatory Product Registration Approval for Second Immune Support Dietary Supplement Designed and Produced by Guardion Health Sciences

Nasdaq Grants Guardion HealthSciences an Extension to March 15,2021 to Regain Compliance with the $1.00 Minimum Bid Price Rule

Guardion Health Sciences Appoints Seasoned Nutritional Products Industry Leader Bret Scholtes as President and Chief Executive Officer

Guardion Health Sciences Announces Development of New Vision/Energy Support Drink – EPIQ-V

Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2020

Guardion Health Sciences Announces Newly-Published Data Demonstrating Superior Visual Function and Macular Carotenoid Changes Using Guardion’s Proprietary Lumega-Z® Formulation Compared to AREDS-2 Formulation

Guardion Provides Answers to Frequently Asked Questions Regarding the Reasons for Approving the Reverse Stock Split Proposal at Upcoming 2020 Annual Stockholders’ Meeting

Guardion Health Sciences Announces Investigator-Initiated Clinical Trial of Lumega-Z

Guardion Provides Update on Strategy, Business Plans and Initiatives

Guardion Announces Virtual Annual Meeting of Stockholders

Guardion Health Sciences Product Licensee Receives Registration Approval in Malaysia for Immune Support Supplement

Guardion Health Sciences Reports Results of Operations for Quarter Ended June 30, 2020

Guardion Health Sciences to Report Second Quarter 2020 Financial Results on August 12, 2020

Guardion Health Sciences Adds Experienced Vice President and Chief Financial Officer to Executive Management Team

Guardion Subsidiary VectorVision Receives Approval from Korean Intellectual Property Office for CSV-2000 Trademark

Guardion Health Sciences Announces Submission of Patent Application for Treatment of Certain Underlying Conditions Related to Eye Disease

Guardion Health Sciences Completes Delivery of $875,000 Order to Malaysian Corporate Customer

Guardion Health Sciences Names Dr. David Evans as Interim President and Interim Chief Executive Officer

Guardion Health Sciences Reports First Quarter 2020 Financial Results and Provides Corporate Update

Lumega-Z® Demonstrates Superiority in a Head-to-Head Study Showing Better Bioavailability of Carotenoids and Restoring Macular Pigment Density

Guardion Health Sciences to Present at the April 2020 Virtual Investor Summit

Guardion Health Sciences Announces Launch of acuMMUNE: An Immuno-Supportive/Anti-Oxidant Complex

Guardion Health Sciences Receives Initial Order from Malaysian Company for Exclusive Immuno-Supportive Formula

Guardion Health Sciences Reports 2019 Year End Results and Provides Corporate Update and Overview

Guardion Health Sciences Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Guardion Health Sciences Receives $3.5 Million from Exercise of Warrants

Guardion Health Sciences Selected by Malaysian Listed Company to Develop an Immuno-Supportive Formula

Guardion® Announces Development of Unique Immuno-Supportive Complex Targeting Upper Respiratory Tract Infections

Guardion® Appoints Experienced Executive to Lead Development and Expansion of Recently-Acquired NutriGuard Business Line

Guardion Health Sciences, Inc. Reports Results for the Three and Nine Months Ended September 30, 2019

Guardion Health Sciences Closes $8.4 Million Underwritten Public Offering

Guardion® Appoints Experienced Executive to Lead Development and Expansion of Recently-Acquired NutriGuard Business Line

Guardion Health Sciences Announces Pricing of $8.4 Million Underwritten Public Offering

Guardion® Receives approval from USPTO for expanded claims for its Proprietary Medical Device, the MAPCAT SF

Guardion® Announces Statistically Significant Blood Assay Study Results

Guardion Health Sciences Acquires the NutriGuard Brand of Products

Guardion Launches VectorVision CSV-2000 Standardized Contrast Sensitivity Test

Guardion Health Sciences Announces an Increase in the Pricing of its Previously Announced Underwritten
Public Offering

Guardion Health Sciences Closes $5.8 Million Underwritten Public Offering

Guardion Health Sciences Announces Pricing of $5.2 Million Underwritten Public Offering

Guardion Health Sciences Reports June 30, 2019 Interim Results of Operations

Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the European Union

Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the Hong Kong Patents Registry

Guardion Launches Second Ocular Health Formula ‘GlaucoCetin’

Guardion’s Lumega-Z Formula Associated with Substantial Clinical Improvement in Patients Contrast Sensitivity Visual Function (CSF) vs AREDS 2

Guardion’s Lumega-Z Formula Associated with Improved Vision in Patients with Severe Glaucoma

Guardion Health Sciences, Inc. Receives Official Trademark Registrations in China

Guardion Health Sciences, Inc. Announces Closing of Initial Public Offering

Results of Lumega-Z Data to be Presented at ARVO

Guardion Health Sciences, Inc. Announces Pricing of Initial Public Offering

Guardion Health Sciences Receives Methods Patents to Standardize Vision Testing

Guardion Health Sciences Exhibiting at Caribbean Eye Meeting

Guardion Health Sciences Closes $5 Million Common Equity Financing

Guardion Health Sciences acquires VectorVision

Guardion Health Sciences announces completion of Series B funding round, raising over $3 million

International Carotenoid Society honors Advisory Board Members with Fellowship Awards

Guardion Health Sciences signs Letter of Intent to acquire VectorVision

Guardion Health Sciences, Inc. completes registration with SEC, becomes a Public Reporting Company

Guardion Health Sciences Medical Advisory Board Member Receives Prestigious Award For Excellence In Ophthalmology Research And Service

Guardion Health Sciences receives patent for its diagnostic device, the MapcatSF

P Dee G Stephenson, M.D. joins Guardion Health Sciences Medical Advisory Board

Bridgitte Shen Lee, O.D. joins Guardion Health Sciences Medical Advisory Board

Guardion Health Sciences Files Form S-1 Registration Statement under the Securities Act of 1933

Macular pigment specialists, Guardion Health Sciences appoints Gordon Bethwaite as Vice President

Col (R) Donald A. Gagliano, MD, MHA, FACHE, CPC joins Guardion’s Science Advisory Board

Macular Carotenoids Conference 2013

Professors Bone and Landrum honored at the Macular Carotenoids & AMD Conference 2011 in Cambridge, UK.

GHS Scientists to Present at the Macular Carotenoids & AMD Conference 2011

Upcoming Events:

Past Events:

Q2 2020 financial results conference call 
Presentation: Wednesday, August 12 at 1:30 pm PT (4:30 pm ET)
Webcast: https://globalmeet.webcasts.com/starthere.jsp?ei=1354277&tp_key=bc75213e8f

April 2020 Virtual Investor Summit
Presentation: Wednesday, April 22 at 1:30 PM ET
Webcast: https://78449.themediaframe.com/dataconf/productusers/lavoie/mediaframe/37340/indexl.html